Introduction. Critical limb lschemia (CLI) and particularly diabetic foot (DF) are still considered “Cinderella” in our departments. Anyway, the presence of arterial obstructive disease increases the risk of amputation by itself; when it is associated with foot infection, the risk of amputation is greatly increased. Methods. From January 2007 to December 2011, 375 patients with DF infection and CLI have been admitted to our Unit; from 2007 to 2009, 192 patients (Group A) underwent surgical debridement of the lesion followed by a delayed revascularization; from 2010 to 2011, 183 patients (Group B) were treated following a new 4-step protocol: (1) early diagnosis with a 24？h on call DF team; (2) urgent treatment of severe foot infection with an aggressive surgical debridement; (3) early revascularization within 24 hours; (4) definitive treatment: wound healing, reconstructive surgery, and orthesis. We reported rates of mortality, major amputation, and foot healing at 6 months of followup. Results. The majority of patients in both groups were male; no statistical differences in medical history and clinical condition were reported at the baseline. The main difference between the two groups was the mean time from debridement to revascularization (3 days in Group A and 24 hours in Group B). After 6 months of follow-up, mortality was 11% in Group A versus 4.4% in Group B. Major amputation rate was 39.6% and 24.6% in Groups A and B, respectively. Wound healing was achieved in 17.8% in Group A and 20.8% in Group B. Conclusions. This protocol requires a lot of professional skills that should to reach the goal to avoid major amputations in patients with DF. Only an interdisciplinary integrated DF team and an early intervention may significantly impact the outcome of our patients: “Time is Tissue”! 1. Introduction Diabetes is a chronic disease that approximately involves 350 million people (6.5%) worldwide, with an increasing trend to some 440 million (7.8%) by 2030 [1]. It is burdened by microangiopathic (nephropathy, retinopathy, and neuropathy) and macroangiopathic complications (cardiovascular disease and fatal or nonfatal stroke). Cardiovascular diseases are the leading cause of morbidity and mortality in diabetes mellitus, especially in type II [2]. Overall, myocardial infarction, fatal or nonfatal stroke, and amputations are 2 to 4 times more frequent, and global cardiovascular risk is about 3 times higher in diabetic patients than in the nondiabetic population [3]. By the way, in a Finnish study, mortality in patients with type II diabetes without prior
References
[1]
World Health Organisation, Fact sheet no. 312, 2011.
[2]
L. O. Watkins, “Epidemiology and burden of cardiovascular disease,” Clinical Cardiology, vol. 27, no. 6, pp. III2–III6, 2004.
[3]
J. Stamler, O. Vaccaro, J. D. Neaton, and D. Wentworth, “Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial,” Diabetes Care, vol. 16, no. 2, pp. 434–444, 1993.
[4]
S. M. Haffner, S. Lehto, T. R？nnemaa, K. Py？r？l？, and M. Laakso, “Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction,” New England Journal of Medicine, vol. 339, no. 4, pp. 229–234, 1998.
[5]
American Diabetes Association, “Diabetes 1993 Vital Statistics,” ADA publication, no. PMDIVS93, 1993.
[6]
A. J. M. Boulton, “End-stage complications of diabetic neuropathy: foot ulceration,” Canadian Journal of Neurological Sciences, vol. 21, no. 4, pp. S18–S22, 1994.
[7]
American Diabetes Association, “Direct and indirect costs of diabetes in the United States in 1992,” ADA publication, no. PMDIC92, 1992.
[8]
H. J. Murray and A. J. M. Boulton, “The pathophysiology of diabetic foot ulceration,” Clinics in Podiatric Medicine and Surgery, vol. 12, no. 1, pp. 1–17, 1995.
[9]
N. R. Waugh, “Amputations in diabetic patients: a review of rates, relative risks and resource use,” Community Medicine, vol. 10, no. 4, pp. 279–288, 1988.
[10]
M. E. Levin, “Preventing amputation in the patient with diabetes,” Diabetes Care, vol. 18, no. 10, pp. 1383–1394, 1995.
[11]
C. Caravaggi, “Integrated surgical protocol for the treatment of the infected diabetic foot,” Journal of Cardiovascular Surgery, vol. 53, no. 1, pp. 23–30, 2012.
[12]
J. Y. Poirier, E. Garin, C. Derrien et al., “Diagnosis of osteomyelitis in the diabetic foot with a 99mTc-HMPAO leucocyte scintigraphy combined with a 99mTc-MDP bone scintigraphy,” Diabetes and Metabolism, vol. 28, no. 6, pp. 485–490, 2002.
[13]
Standards of Medical Care in Diabetesd, “Diabetes,” 2012, http://www.oeglmkc.at/labor/ADA-Standards-Diabetes-Care-2012.
[14]
S. Vuorisalo, M. Venermo, and M. Lep？ntalo, “Treatment of diabeticfootulcers,” Journal of Cardiovascular Surgery, vol. 50, no. 3, pp. 275–291, 2009.
[15]
A. L. Lima, P. R. Oliveira, V. C. Carvalho, et al., “Microbiology of diabeticfootinfections: role of ertapenem,” Drugs Today, vol. 49, supplement A, pp. 1–20, 2013.
[16]
C. Setacci, E. Chisci, G. de Donato, F. Setacci, F. Iacoponi, and G. Galzerano, “Subintimal angioplasty with the aid of a re-entry device for TASC C and D lesions of the SFA,” European Journal of Vascular and Endovascular Surgery, vol. 38, no. 1, pp. 76–87, 2009.
[17]
C. Setacci, G. de Donato, F. Setacci, and E. Chisci, “Ischemic foot: definition, etiology and angiosome concept,” Journal of Cardiovascular Surgery, vol. 51, no. 2, pp. 223–231, 2010.
[18]
Joint News Release WHO/IDF, 2011.
[19]
A. J. Boulton, L. Vileikyte, G. Ragnarson-Tennvall, and J. Apelqvist, “The global burden of diabetic foot disease,” The Lancet, vol. 366, no. 9498, pp. 1719–1724, 2005.
[20]
N. Singh, D. G. Armstrong, and B. A. Lipsky, “Preventing foot ulcers in patients with diabetes,” Journal of the American Medical Association, vol. 293, no. 2, pp. 217–228, 2005.
[21]
L. Prompers, N. Schaper, J. Apelqvist et al., “Prediction of outcome in individuals with diabetic foot ulcers: focus on the differences between individuals with and without peripheral arterial disease. The EURODIALE Study,” Diabetologia, vol. 51, no. 5, pp. 747–755, 2008.
[22]
D. M. Molenaar, P. J. Palumbo, and W. R. R. E. Wilson and Ritts Jr., “Leukocyte chemotaxis in diabetic patients and their nondiabetic first degree relatives,” Diabetes, vol. 25, no. 2, pp. 880–883, 1976.
[23]
J. E. Repine, C. C. Clawson, and F. C. Goetz, “Bactericidal function of neutrophils from patients with acute bacterial infections and from diabetics,” Journal of Infectious Diseases, vol. 142, no. 6, pp. 869–875, 1980.
[24]
S. Katz, B. Klein, and I. Elian, “Phagocytotic activity of monocytes from diabetic patients,” Diabetes Care, vol. 6, no. 5, pp. 479–482, 1983.
[25]
R. G. Frykberg, “Diabetes foot ulcerations,” in The High Risk Foot in Diabetes Mellitus, R. G. Frykberg, Ed., pp. 151–195, Churchill-Livingstone, New York, NY, USA, 1991.
[26]
“Second European consensus document on chronic critical leg ischemia,” European Journal of Vascular Surgery, vol. 6, supplement A, pp. 1–32, 1992.
[27]
E. W. Gregg, P. Sorlie, R. Paulose-Ram et al., “Prevalence of lower-extremity disease in the U.S. adult population ≥40 years of age with and without diabetes: 1999-2000 National Health and Nutrition Examination Survey,” Diabetes Care, vol. 27, no. 7, pp. 1591–1597, 2004.
[28]
J. A. Beckman, M. A. Creager, and P. Libby, “Diabetes and atherosclerosis epidemiology, pathophysiology, and management,” Journal of the American Medical Association, vol. 287, no. 19, pp. 2570–2581, 2002.
[29]
N. C. Dolan, K. Liu, M. H. Criqui et al., “Peripheral artery disease, diabetes, and reduced lower extremity functioning,” Diabetes Care, vol. 25, no. 1, pp. 113–120, 2002.
[30]
E. Faglia, F. Favales, A. Quarantiello et al., “Angiographic evaluation of peripheral arterial occlusive disease and its role as a prognostic determinant for major amputation in diabetic subjects with foot ulcers,” Diabetes Care, vol. 21, no. 4, pp. 625–630, 1998.
[31]
J. Malmstedt, K. Leander, E. Wahlberg, L. Karlstrom, L. Alfredsson, and J. Swedenborg, “Outcome after leg bypass surgery for critical limb ischemia is poor in patients with diabetes. A population-based cohort study,” Diabetes Care, vol. 31, no. 5, pp. 887–892, 2008.
[32]
E. Faglia, L. Dalla Paola, G. Clerici et al., “Peripheral angioplasty as the first-choice revascularization procedure in diabetic patients with critical limb ischemia: prospective study of 993 consecutive patients hospitalized and followed between 1999 and 2003,” European Journal of Vascular and Endovascular Surgery, vol. 29, no. 6, pp. 620–627, 2005.
[33]
F. Dick, N. Diehm, A. Galimanis, M. Husmann, J. Schmidli, and I. Baumgartner, “Surgical or endovascular revascularization in patients with critical limb ischemia: influence of diabetes mellitus on clinical outcome,” Journal of Vascular Surgery, vol. 45, no. 4, pp. 751–761, 2007.
[34]
R. Ferraresi, M. Centola, M. Ferlini et al., “Long-term outcomes after angioplasty of isolated, below-the-knee arteries in diabetic patients with critical limb ischaemia,” European Journal of Vascular and Endovascular Surgery, vol. 37, no. 3, pp. 336–342, 2009.
[35]
L. Graziani and A. Piaggesi, “Indications and clinical outcomes for below knee endovascular therapy: review article,” Catheterization and Cardiovascular Interventions, vol. 75, no. 3, pp. 433–443, 2010.
[36]
S. deFranciscis, L. Gallelli, L. Battaglia, et al., “Cilostazol prevents foot ulcers in diabetic patients with peripheral vascular disease,” International Wound Journal, 2013.
[37]
A. Bolia, “Subintimal angioplasty in lower limb ischaemia,” Journal of Cardiovascular Surgery, vol. 46, no. 4, pp. 385–394, 2005.
[38]
M. Montero-Baker, A. Schmidt, S. Br？unlich et al., “Retrograde approach for complex popliteal and tibioperoneal occlusions,” Journal of Endovascular Therapy, vol. 15, no. 5, pp. 594–604, 2008.
[39]
D. J. Spinosa, N. L. Harthun, E. A. Bissonette et al., “Subintimal arterial flossing with antegrade-retrograde intervention (SAFARI) for subintimal recanalization to treat chronic critical limb ischemia,” Journal of Vascular and Interventional Radiology, vol. 16, no. 1, pp. 37–44, 2005.
[40]
R. Gandini, V. Pipitone, M. Stefanini et al., “The “Safari” technique to perform difficult subintimal infragenicular vessels,” Cardiovascular and Interventional Radiology, vol. 30, no. 3, pp. 469–473, 2007.
[41]
L. Graziani, A. Silvestro, L. Monge et al., “Transluminal angioplasty of peroneal artery branches in diabetics: initial technical experience,” Cardiovascular and Interventional Radiology, vol. 31, no. 1, pp. 49–55, 2008.
[42]
M. Fusaro, L. Dalla Paola, C. Brigato et al., “Plantar to dorsalis pedis artery subintimal angioplasty in a patient with critical foot ischemia: a novel technique in the armamentarium of the peripheral interventionist,” Journal of Cardiovascular Medicine, vol. 8, no. 11, pp. 977–980, 2007.
[43]
M. Manzi, M. Fusaro, T. Ceccacci, G. Erente, L. Dalla Paola, and E. Brocco, “Clinical results of below-the knee intervention using pedal-plantar loop technique for the revascularization of foot arteries,” Journal of Cardiovascular Surgery, vol. 50, no. 3, pp. 331–337, 2009.
[44]
M. S. Conte, “Diabetics revascularization: endovascular versus open bypass—do we have then answer?” Seminars in Vascular Surgery, vol. 25, pp. 108–114, 2012.
[45]
E. Faglia, G. Clerici, M. Caminiti, A. Quarantiello, M. Gino, and A. Morabito, “The role of early surgical debridement and revascularization in diabetic patients with deep foot space abscess: retrospective review of 106 diabetic patients,” Journal of Foot and Ankle Surgery, vol. 45, no. 4, pp. 220–226, 2006.
[46]
M. Lep？ntalo, J. Apelqvist, C. Setacci, et al., “Chapter V: diabetic foot,” European Journal of Vascular and Endovascular Surgery, vol. 42, supplement 2, pp. S60–S74, 2011.
